No.85 Hospital, Changning, Shanghai, China
12
1
1
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
33%
4 trials in Phase 3/4
13%
1 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
FibroTouch Non-invasive Evaluation of Liver Fibrosis and Cirrhosis
Role: collaborator
A Study of Ultrashort PRS Regimen V in the Treatment of MDR-TB
Role: collaborator
Efficacy of Second Forward-view Examination of Left Colon for Adenoma Detection During Colonoscopy
Role: collaborator
A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB
Role: collaborator
Clinical Study of New Intensive Treatment Regimen for Severe Nontuberculous Mycobacterial Pulmonary Disease
Role: collaborator
9 Minutes for Tandem Colonoscopy Withdrawal
Role: collaborator
Pilot Clinical Trial of PRS TB Regimen I - Phase II
Role: collaborator
9 Minutes for Colonoscopy Withdrawal
Role: collaborator
Supine Position for Colonoscopy Insertion
Role: collaborator
Comparison of Acoustic Attenuation Parameter Using FibroTouch With Liver Biopsy for Diagnosis of Hepatic Steatosis
Role: collaborator
Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy
Role: collaborator
Human Umbilical Cord Mesenchymal Stem Cells Transplantation for Patients With Decompensated Liver Cirrhosis
Role: collaborator
All 12 trials loaded